Abstract: Purified BMP-5 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
June 3, 1997
Assignee:
Genetics Institute, Inc.
Inventors:
John M. Wozney, Vicki A. Rosen, Elizabeth A. Wang
Abstract: Disclosed is a human TGF.alpha.-H1 polypeptide and DNA (RNA) encoding such TGF.alpha.-H1 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and for producing antibodies and antagonists against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic, therapeutic and/or prophylactic effects against various diseases. Also provided, are methods of using the antibodies and antagonists to inhibit TGF.alpha.-H1 for therapeutic purposes.
Type:
Grant
Filed:
March 8, 1994
Date of Patent:
May 27, 1997
Assignee:
Human Genome Sciences, Inc.
Inventors:
Paul S. Meissner, Rebecca A. Fuldner, Mark D. Adams
Abstract: Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.
Type:
Grant
Filed:
June 10, 1993
Date of Patent:
April 8, 1997
Assignee:
Oncogen Limited Partnership
Inventors:
Mohammed Shoyab, Joyce M. Zarling, Hans Marquardt, Marcia B. Hanson, Najma Malik, Peter S. Linsley, Timothy M. Rose, Anthony F. Purchio
Abstract: Full-length cDNA clones have been isolated encoding purified augmenter of liver regeneration (ALR) polypeptides prepared from the cytosol of livers from weanling rats and from humans. The full-length clone from the rat is a 1226 bp cDNA containing an 81 bp 5'-untranslated region, a 594 bp coding region and a 551 bp 3'-untranslated region. The coding region encodes three proteins with estimated molecular weights of 15,081, 20,193 and 22,835. The full-length clone from the human consists of a 727 bp cDNA containing a 4 bp 5'-untranslated region, a 615 bp coding region and a 108 bp 3'-untranslated region, including the termination codon TAG and the poly (A) region. The 615 bp coding region encodes four proteins, human ALR-V1, ALR-V2, ALR-V3 and ALR, having estimated molecular weights of 23,448, 20,834, 20,703 and 15,028, respectively.
Type:
Grant
Filed:
January 3, 1995
Date of Patent:
March 4, 1997
Assignee:
University of Pittsburgh
Inventors:
Antonio T. Francavilla, Michio Hagiya, Thomas E. Starzl
Abstract: There is disclosed the nucleic acid and amino acid sequences for the human PTH-Like Peptide and derivatives. PTH-Like Peptide is the humoral mediator of humoral hypercalcemia of malignany or HHM which is common in patients with squamous carcinomas or renal, bladder or ovarian carcinomas with little or no evidence of skeletal disease.
Type:
Grant
Filed:
June 21, 1994
Date of Patent:
February 25, 1997
Assignee:
Yale University
Inventors:
Arthur E. Broadus, Andrew F. Stewart, Marguerite Mangin